Tonix Pharmaceuticals Holding Corp.
TNXPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology,. With a market capitalization of $184.3M, it sits in micro-cap territory. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Market Cap
$184.3M
Beta
1.65
P/E (TTM)
—
P/E (Fwd)
-1.48
EPS (TTM)
$-15.42
EPS (Fwd)
$-7.80
ROE
-72.3%
ROA
-41.9%
Cash
$185.5M
Total Debt
$1.3M
Free CF
-$76.7M
52W Change
-74.2%
Annual Financials
Cash vs Debt
Where TNXP stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, TNXP finished 23.67% below its 150-day moving average ($14.49) and 29.28% below its 200-day moving average ($15.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNXP overbought or oversold?
At the July 15, 2026 close, TNXP's RSI(14) was 41.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tonix Pharmaceuticals Holding Corp. holds $185.5M in cash against $1.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$76.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -72.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, TNXP tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TNXP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.